Aging Drug Network Predictions Need Clinical Trials

How Can Network Medicine Find Drugs That Target Aging?

Aging does not arise from one molecular defect, making it difficult to treat as though it were a conventional disease with a single drug target. The hallmarks-of-aging framework instead describes interacting processes such as genomic instability, loss of proteostasis, mitochondrial dysfunction, cellular senescence and altered intercellular communication. Network-based research can map these processes against known drug targets and identify medicines whose effects may reach several relevant pathways.

This strategy is useful for generating hypotheses because it evaluates relationships that may be missed when researchers examine one gene or protein at a time. A computationally prioritized medicine is not automatically an anti-aging treatment, however. Network proximity and biological plausibility cannot establish an effective dose, demonstrate clinical benefit or exclude harmful interactions in older adults.

Why Are Repurposed Medicines Attractive for Healthy-Aging Research?

Drug repurposing investigates whether a medicine developed for one condition could benefit another. Researchers may already understand the drug's pharmacology, common adverse effects and major contraindications, although those findings may not apply fully to a healthier population taking treatment for many years. Existing clinical experience can help investigators design trials, but it does not replace trials for the proposed aging-related indication.

The risk-benefit threshold is especially demanding when treatment is intended to prevent future disease in people who are not currently ill. Even an uncommon adverse effect can become important when a large population might use a medicine over long periods. Older adults also frequently take several prescriptions, increasing the importance of studying drug interactions, kidney and liver function, frailty and differences between biological and chronological age.

What Evidence Would Make an Aging-Targeted Drug Clinically Useful?

Useful trials must measure outcomes that matter to patients, such as disability, cardiovascular events, cognitive decline, cancer, hospitalization or survival without major chronic disease. Changes in a laboratory biomarker may support a biological mechanism, but they do not necessarily prove that people remain healthier or live longer. Trials also need adequate follow-up because both benefits and delayed harms may take time to emerge.

Future research should determine whether candidates work broadly across aging-related conditions or only in people with particular diseases, molecular profiles or risk factors. Until such evidence is available, network-selected drugs should be treated as research candidates rather than prescriptions for longevity. Patients should not use prescription medicines off-label for anti-aging purposes without individualized medical advice.